Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	75.63	83.6	7.35	16.05
Cash & Short-Term Investments	75.63	83.6	7.35	16.05
Cash Growth	928.92%	1037.44%	-54.21%	-
Accounts Receivable	-	0.36	-	-
Other Receivables	1.98	1.98	-	-
Receivables	1.98	2.34	-	-
Prepaid Expenses	1.84	2.3	0.2	0.47
Total Current Assets	79.44	88.23	7.55	16.52
Total Assets	79.44	88.23	7.55	16.52
Accounts Payable	4.44	4.59	0.94	3.18
Accrued Expenses	1.74	4.29	1.26	2.44
Other Current Liabilities	2.8	3.17	0.17	0.16
Total Current Liabilities	8.98	12.04	2.36	5.78
Long-Term Debt	13.16	11.94	8.05	32.42
Other Long-Term Liabilities	1.72	1.65	1.01	1.5
Total Liabilities	23.86	25.63	11.43	39.7
Common Stock	0.01	0.01	-	-
Additional Paid-In Capital	157.49	156.33	1.82	1.22
Retained Earnings	-101.92	-93.74	-76.3	-94.99
Comprehensive Income & Other	-0	0	-	-
Total Common Equity	55.58	62.61	-74.48	-93.78
Shareholders' Equity	55.58	62.61	-3.88	-23.17
Total Liabilities & Equity	79.44	88.23	7.55	16.52
Total Debt	13.16	11.94	8.05	32.42
Net Cash (Debt)	62.47	71.66	-0.7	-16.36
Net Cash Per Share	13.77	32.19	-0.39	-2.86
Filing Date Shares Outstanding	11.06	11.02	5.72	5.72
Total Common Shares Outstanding	11.02	11.01	5.72	5.72
Working Capital	70.46	76.2	5.19	10.74
Book Value Per Share	5.04	5.69	-13.02	-16.40
Tangible Book Value	55.58	62.61	-74.48	-93.78
Tangible Book Value Per Share	5.04	5.69	-13.02	-16.40

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q